Zomedica/ZOM

$0.14

-2.52%
-
1D1W1MYTD1YMAX

About Zomedica

Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).

Ticker

ZOM

Sector

Healthcare

Trading on

AMEX

Industry

Fish/Livestock

CEO

Larry Heaton

Employees

144

Headquarters

Ann arbor, United States

Zomedica Metrics

BasicAdvanced
$132.29M
Market cap
-
P/E ratio
-$0.04
EPS
1.00
Beta
-
Dividend rate
$132.29M
1.00045
$0.25
$0.12
5.12M
11.059
10.491
-12.96%
-13.61%
-13.39%
5.253
0.551
1.075
33.05%
-102.88%

What the Analysts think about Zomedica

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
214.29% upside
High $0.44
Low $0.44
$0.14
Current price
$0.44
Average price target

Zomedica Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-306.84% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$7.3M
15.87%
Net income
$-22.4M
5,500%
Profit margin
-306.84%
4,739.75%

Zomedica Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.01
-$0.01
-$0.00
-$0.01
-
Expected
$0.00
$0.00
$0.00
$0.00
$0.00
Surprise
-∞%
-∞%
-∞%
-∞%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Zomedica stock?

Zomedica (ZOM) has a market cap of $132.29M as of April 14, 2024.

What is the P/E ratio for Zomedica stock?

The price to earnings (P/E) ratio for Zomedica (ZOM) stock is 0 as of April 14, 2024.

Does Zomedica stock pay dividends?

No, Zomedica (ZOM) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Zomedica dividend payment date?

Zomedica (ZOM) stock does not pay dividends to its shareholders.

What is the beta indicator for Zomedica?

Zomedica (ZOM) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Zomedica stock price target?

The target price for Zomedica (ZOM) stock is $0.44, which is 214.29% above the current price of $0.14. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Zomedica stock

Buy or sell Zomedica stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing